The known specificity of STn for malignant tissue in combination with the high affinity and STn-specific selectivity of the mAbs presented herein warrant further investigation for anti-STn ADCs as single agent or combination therapy in the clinical setting, specifically in patients with STn-expressing tumor cells. Here, EEF1A2 is linked to neoplasm.